CereVasc concludes patient enrolment in STRIDE trial of eShunt

CereVasc has concluded patient enrolment in its STRIDE study, assessing the safety and effectiveness of the eShunt system for NPH. The outcomes are intended to form the clinical basis for CereVasc’s PMA submission to the FDA. The trial will compare the eShunt System directly with the current standard treatment. Credit: RusAKphoto / Shutterstock.com. CereVasc has concluded patient enrolment in its STRIDE pivotal study, assessing the safety and effectiveness of the investigational eShunt System for normal pressure hydrocephalus (NPH). The enrolment was completed across 32 clinical sites, with the study now progressing through the remaining treatment and follow-up steps for patients…

Source: Medical Device Network